Before Bayh-Dole: Public research funding, patents, and pharmaceutical innovation (1945-1965)

Industrial and Corporate Change

Volumn 20, Issue 3, 2011, Pages 721-749

  Mazzoleni, Roberto ^a  

^a HOFSTRA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; INNOVATION; REGULATORY FRAMEWORK; RESEARCH;

EID: 79957848822     PISSN: 09606491     EISSN: 14643650     Source Type: Journal    
DOI: 10.1093/icc/dtr017     Document Type: Article

References (41)

1. Athreye, S. and A. Godley (2009), 'Internationalization and technological leapfrogging in the pharmaceutical industry,' Industrial and Corporate Change, 18, 295-323.
2. Berman, E. P. (2008), 'Why did universities start patenting? Institutions-building and the road to the Bayh-Dole Act,' Social Studies of Science, 38, 835-871.
3. Chandler, A. D. (2005), Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries. Harvard University Press: Cambridge, MA.
4. Cohen, W. M., R. R. Nelson and J. P. Walsh (2000), Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not). Working Paper 7552, National Bureau of Economic Research: Cambridge, MA.
5. Comanor, W. S. (1964), 'Research and competitive product differentiation in the pharmaceutical industry in the United States,' Economica, 31, 372-384.
6. Comanor, W. S. (1966), 'The drug industry and medical research: the economics of the Kefauver Committee investigations,' The Journal of Business, 39(1), Part 1, 12-18.
7. Comptroller General of the United States. (1968), Report to the Congress: Problem Areas Affecting Usefulness of Results of Government-Sponsored Research in Medicinal Chemistry. Government Printing Office: Washington, DC. Reprinted in US Senate (1978), Government Patent Policies: Institutional Patent Agreements, Part I, Hearings Before the Subcommittee on Monopoly and Anticompetitive Activities, Senate Select Committee on Small Business, 95th Congress 2nd Session, pp.103-146.
8. Costello, P. M. (1968), 'The tetracycline conspiracy: structure, conduct, and performance in the drug industry,' Antitrust Law and Economics Review, 1(4), 5.
9. Dutfield, G. (2009), Intellectual Property Rights and the Life Science Industries: Past, Present and Future. 2nd edn. World Scientific Publishing: Singapore.
10. Eisenberg, R. S. (1996), 'Public research and private development: patents and technology transfer in government-sponsored research,' Virginia Law Review, 82, 1663-1727.
11. Endicott, K. M. and E. M. Allen (1953), 'The growth of medical research and the role of public health service research grants,' Science, 118, 337-343.
12. Facchinetti, N. J. and W. M. Dickson (1982), 'Access to generic drugs in the 1950s: the politics of a social problem,' American Journal of Public Health, 72(5), 468-475.
13. Federal Trade Commission. (1958), Economic Report on Antibiotics Manufacture. United States Government Printing Office: Washington, DC.
14. Furman, J. L. and M. MacGarvie (2009), 'Academic collaboration and organizational innovation: the development of research capabilities in the US pharmaceutical industry, 1927-1946,' Industrial and Corporate Change, 18, 929-961.
15. Harbridge House Commission. (1968), Government Patent Policy Study, Final Report for the Federal Council for Science and Technology Committee on Government Patent Policy. Reprinted in US House of Representatives (1976), Background Materials on Government Patent Policies: Reports of Committees, Commissions, and Major Studies, House Committee on Science and Technology, 94th Congress 2nd Session, pp. 69-140.
16. King, D. C. (1968), Marketing Prescription Drugs. University of Michigan Press: Ann Arbor, MI.
17. Kingston, W. (2000), 'Antibiotics, invention and innovation,' Research Policy, 29, 679-710.
18. Lewis, T. R., J. H. Reichman and A. D. So (2007), 'The case for public funding and public oversight of clinical trials,' The Economists' Voice, 4(1), art. 3.
19. Liebenau, J. (1987), Medical Science and Medical Industry: The Formation of the American Pharmaceutical Industry. Johns Hopkins University Press: Baltimore, MD.
20. Lindsay, D. R. and E. M. Allen (1961), 'Medical research: past support, future directions,' Science, 134, 2017-2024.
21. Mahoney, T. (1959), The Merchants of Life: An Account of the American Pharmaceutical Industry. Harper: New York.
22. Mansfield, E. (1986), 'Patents and innovation: an empirical study,' Management Science, 32, 173-181.
23. Miller, H. D. Jr. (1967), 'Patent license restrictions in the prescription drug industry,' Virginia Law Review, 53, 1283-1313.
24. Mowery, D. C., R. R. Nelson, B. N. Sampat and A. A. Ziedonis (2004), Ivory Tower and Industrial Innovation: University-Industry Technology Transfer Before and After the Bayh-Dole Act. Stanford University Press: Stanford, CA.
25. National Research Council. (1983), The Competitive Status of the U.S. Pharmaceutical Industry: The Influences of Technology in Determining International Industrial Competitive Advantage. National Academy Press: Washington, DC.
26. Parent, K. A. (1966), 'Inventions resulting from public health service extramural grants and awards,' Public Health Reports, 81, 659-670.
27. Schwartzman, D. (1975), The Expected Return from Pharmaceutical Research: Sources of New Drugs and the Profitability of R&D Investment. American Enterprise Institute for Policy Research: Washington, DC.
28. Steele, H. (1962), 'Monopoly and competition in the ethical drugs market,' Journal of Law and Economics, 5, 131-163.
29. Steele, H. (1964), 'Patent restrictions and price competition in the ethical drugs industry,' Journal of Industrial Economics, 12, 198-223.
30. Swann, J. P. (1988), Academic Scientists and the Pharmaceutical Industry: Cooperative Research in Twentieth-Century America. John Hopkins University Press: Baltimore, MD.
31. Temin, P. (1979a), 'Technology, regulation, and market structure in the modern pharmaceutical industry,' Bell Journal of Economics, 10, 429-446.
32. Temin, P. (1979b), Taking Your Medicine: Drug Regulation in the United States. Harvard University Press: Cambridge, MA.
33. Thomas, L. G. (1990), 'Regulation and firm size: FDA impacts on innovation,' RAND Journal of Economics, 21, 497-517.
34. Thompson, W. F. (1959), 'Pharmaceutical research and patents,' Journal of the Patent Office Society, 41, 70-73.
35. US Senate. (1960a), Patent Practices of the Department of Health, Education, and Welfare - Preliminary Report of the Subcommittee on Patents, Trademarks, and Copyrights of the Senate Committee on the Judiciary, 86th Congress, 1st Session. US Government Printing Office: Washington, DC.
36. US Senate. (1960b), Administered Prices - Part 14, Administered Prices in the Drug Industry (Corticosteroids), Hearings Before the Subcommittee on Antitrust and Monopoly of theCommittee on the Judiciary Pursuant to S.Res. 57, 86th Congress 1st Session. US Government Printing Office: Washington, DC.
37. US Senate. (1961), An Analytical History of the Patent Policy of the Department of Health, Education, and Welfare - Subcommittee on Patents, Trademarks, and Copyrights of the Senate Committee on the Judiciary, 86th Congress, 2nd Session, Study No. 27. US Government Printing Office: Washington, DC.
38. US Senate. (1965a), Government Patent Policy, Part 1, Hearings Before the Subcommittee on Patents, Trademarks, and Copyrights of the Senate Committee on the Judiciary Pursuant to S. Res. 48, 89th Congress 1st Session. US Government Printing Office: Washington, DC.
39. US Senate. (1965b), Government Patent Policy, Part 2, Hearings Before the Subcommittee on Patents, Trademarks, and Copyrights of the Senate Committee on the Judiciary Pursuant to S. Res. 48, 89th Congress 1st Session. US Government Printing Office: Washington, DC.
40. US Senate. (1978), Government Patent Policies: Institutional Patent Agreements, Part I, Hearings Before the Subcommittee on Monopoly and Anticompetitive Activities, Senate Select Committee on Small Business, 95th Congress 2nd Session. US Government Printing Office: Washington, DC.
41. Walker, H. D. (1971), Market Power and Price Levels in the Ethical Drug Industry. Indiana University Press: Bloomington, IN.